External validation of a simplified BCLC staging system for early hepatocellular carcinoma
Copyright © 2013 Elsevier Ltd. All rights reserved..
BACKGROUND AND AIMS: The aim was to externally validate the capability of a simplified Barcelona Clinic Liver Cancer (s-BCLC) staging system in allocating patients to hepatic resection (HR) and the effect on survival: S-BCLC was defined by only 2 groups: AA included BCLC A1 + A2 classes with alpha-fetoprotein (AFP) ≤ 20 ng/ml and AB included A1 + A2 with AFP > 20 ng/ml plus A3 + A4 subgroups.
METHODS: This study compared a training group (TG) with hepatocellular carcinoma (HCC) submitted to hepatic resection (HR) in Milan with another group of patients, the validation group (VG) in Creteil. All patients underwent ultrasound-guided anatomical resection (<3 segments).
RESULTS: Overall survival got worse from A1 to A4 (p = 0.0271) in TG (n = 132), as well as in VG (n = 100) (p = 0.0044) with a more important overlapping of each curves. According s-BCLC classification, the survival curves of TG (p = 0.0001) and VG (p = 0.0250) showed a definitive separation in two different staging groups. The s-BCLC provided the best predictive accuracy and it also presented the highest separability index and C-statistics in both TG and VG. On the other hand, in the evaluation of discriminatory ability for death, measured by ROC curve areas, the s-BCLC system gave better results than the others.
CONCLUSION: This experience stressed the high value of BCLC system in staging of HCC, but the s-BCLC system seems to be more useful for therapeutic decision making.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology - 39(2013), 8 vom: 05. Aug., Seite 850-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Santambrogio, R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.09.2013 Date Revised 10.12.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejso.2013.05.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM227966058 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM227966058 | ||
| 003 | DE-627 | ||
| 005 | 20231224074840.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejso.2013.05.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0760.xml |
| 035 | |a (DE-627)NLM227966058 | ||
| 035 | |a (NLM)23726257 | ||
| 035 | |a (PII)S0748-7983(13)00372-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Santambrogio, R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a External validation of a simplified BCLC staging system for early hepatocellular carcinoma |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.09.2013 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2013 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND AND AIMS: The aim was to externally validate the capability of a simplified Barcelona Clinic Liver Cancer (s-BCLC) staging system in allocating patients to hepatic resection (HR) and the effect on survival: S-BCLC was defined by only 2 groups: AA included BCLC A1 + A2 classes with alpha-fetoprotein (AFP) ≤ 20 ng/ml and AB included A1 + A2 with AFP > 20 ng/ml plus A3 + A4 subgroups | ||
| 520 | |a METHODS: This study compared a training group (TG) with hepatocellular carcinoma (HCC) submitted to hepatic resection (HR) in Milan with another group of patients, the validation group (VG) in Creteil. All patients underwent ultrasound-guided anatomical resection (<3 segments) | ||
| 520 | |a RESULTS: Overall survival got worse from A1 to A4 (p = 0.0271) in TG (n = 132), as well as in VG (n = 100) (p = 0.0044) with a more important overlapping of each curves. According s-BCLC classification, the survival curves of TG (p = 0.0001) and VG (p = 0.0250) showed a definitive separation in two different staging groups. The s-BCLC provided the best predictive accuracy and it also presented the highest separability index and C-statistics in both TG and VG. On the other hand, in the evaluation of discriminatory ability for death, measured by ROC curve areas, the s-BCLC system gave better results than the others | ||
| 520 | |a CONCLUSION: This experience stressed the high value of BCLC system in staging of HCC, but the s-BCLC system seems to be more useful for therapeutic decision making | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Validation Study | |
| 650 | 4 | |a AASLD | |
| 650 | 4 | |a AFP | |
| 650 | 4 | |a American Association for the Study of Liver Diseases | |
| 650 | 4 | |a BCLC | |
| 650 | 4 | |a Barcelona Clinic Liver Cancer | |
| 650 | 4 | |a HCC | |
| 650 | 4 | |a HR | |
| 650 | 4 | |a Hepatic resection | |
| 650 | 4 | |a Hepato-Pancreato-Biliary Association | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a IHPBA | |
| 650 | 4 | |a IOUS | |
| 650 | 4 | |a LCSGJ | |
| 650 | 4 | |a Laparoscopy | |
| 650 | 4 | |a Liver Cancer Study Group of Japan | |
| 650 | 4 | |a Liver cancer | |
| 650 | 4 | |a Liver cirrhosis | |
| 650 | 4 | |a Radiofrequency ablation | |
| 650 | 4 | |a Staging system | |
| 650 | 4 | |a TG | |
| 650 | 4 | |a Training group | |
| 650 | 4 | |a VG | |
| 650 | 4 | |a Validation group | |
| 650 | 4 | |a alpha-fetoprotein | |
| 650 | 4 | |a hepatic resection | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a intraoperative ultrasonography | |
| 650 | 4 | |a s-BCLC | |
| 650 | 4 | |a simplified system for BCLC stage A | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a alpha-Fetoproteins |2 NLM | |
| 700 | 1 | |a Salceda, J |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, M |e verfasserin |4 aut | |
| 700 | 1 | |a Kluger, M D |e verfasserin |4 aut | |
| 700 | 1 | |a Barabino, M |e verfasserin |4 aut | |
| 700 | 1 | |a Laurent, A |e verfasserin |4 aut | |
| 700 | 1 | |a Opocher, E |e verfasserin |4 aut | |
| 700 | 1 | |a Azoulay, D |e verfasserin |4 aut | |
| 700 | 1 | |a Cherqui, D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology |d 1993 |g 39(2013), 8 vom: 05. Aug., Seite 850-7 |w (DE-627)NLM01262862X |x 1532-2157 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2013 |g number:8 |g day:05 |g month:08 |g pages:850-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejso.2013.05.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2013 |e 8 |b 05 |c 08 |h 850-7 | ||